Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05939453 · ClinicalTrials.gov registry record · NA
Impact of Bright Light Therapy on Prader-Willi Syndrome
A NA study of Mood and Body Weight, sponsored by Maimonides Medical Center.
- Recruiting
- Registry status
- NA
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT05939453: Recruiting NA study of Mood and Body Weight, sponsored by Maimonides Medical Center.
NCT05939453 is a NA study of Mood and Body Weight that is actively recruiting participants, run by Maimonides Medical Center. The registered enrollment target is 30 participants, below the 3,659-participant average among 29 other Mood trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05939453, a NA study of Mood and Body Weight, is actively recruiting participants, sponsored by Maimonides Medical Center.
- RECRUITING
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a placebo controlled clinical trial to assess the utility of light therapy as a sufficient treatment for excessive daytime sleepiness in patients with Prader-Willi Syndrome
Primary Outcome
A positive clinical response will be determined by a rating of 1 or 2 (Very much/Much improved) on the Clinical Global Impression- Improvement (CGI-I) scale at the end of the blinded trial.
Conditions Studied
Interventions
- OTHER Sham Light
- OTHER Bright Light Therapy
Study Locations (1)
New York
- Maimonides Medical Center - Brooklyn
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2023-10-01 |
| Est. Completion | 2026-06 |
| Phase | NA |
What NCT05939453 shows while recruiting
NCT05939453 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 3,659-participant average among 29 other Mood trials with a reported enrollment target (99% lower).
The record links to 6 conditions, with Mood appearing as the primary indexed condition, and to 2 interventions - of which Sham Light is the first listed.
NCT05939453 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT05939453 about?
NCT05939453 is a clinical study titled "Impact of Bright Light Therapy on Prader-Willi Syndrome". This is a placebo controlled clinical trial to assess the utility of light therapy as a sufficient treatment for excessive daytime sleepiness in patients with Prader-Willi Syndrome
What is the current status of trial NCT05939453?
This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2023-10-01. Estimated completion is 2026-06.
What conditions does trial NCT05939453 study?
This clinical trial studies the following conditions: Mood, Body Weight, Behavior, Prader-Willi Syndrome, Excessive Daytime Sleepiness.
What interventions are being tested in trial NCT05939453?
The interventions under investigation include: Sham Light (OTHER), Bright Light Therapy (OTHER).
Who is sponsoring clinical trial NCT05939453?
This trial is sponsored by Maimonides Medical Center, which has 39 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05939453 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mood
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05939453's enrollment target sits among peer trials
30 22nd of 29 higher than 8 of 29 other Mood trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Mood trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Student Exercise and Sleep Timing Study - Part 2
RECRUITING · NA
-
Efficacy and Safety of Shatavari for Treatment of Menopausal Symptoms in Women: A Randomized, Double-blind, Three-arm, Parallel, Placebo-controlled Study
RECRUITING · NA
-
Developing Resilience and Anxiety Management Through the Arts
RECRUITING · NA
-
Use Muscadine Wine Nutraceuticals to Improve Brain Health, Cognition, and Mental Health
RECRUITING · NA
-
Intern Health Study 2024
ACTIVE NOT RECRUITING · NA
-
The Effect of Portion Sizes on Mood
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI